Dizal (688192.SH) Presents Latest Data on Golidocitinib and Birelentinib at 67th ASH Annual Meeting

Dizal Pharma to Present Positive Results of Two Drugs At American Convention

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH): Multiple Studies on Golidocitinib and Birelentinib Selected for 67th ASH Annual Meeting

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH): Multiple Latest Research Findings in Lung Cancer Field Announced at 2025 World Conference on Lung Cancer (WCLC)

Dizal Pharmaceutical Reports 74% H1 Revenue Growth as Core Products Gain Momentum Following Medical Insurance Inclusion

BRIEF-The U.S. FDA Granted Fast Track Designation To Dizal's Birelentinib For Relapsed/Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma

the U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Dizal Pharma to Present Two Lung Cancer Drugs at World Conference on Lung Cancer; Shares Up 6%

Jiangsu Pharmaceutical's Lung Cancer Drug Gets US FDA Approval

Dizal Jiangsu Pharmaceutical Completes Patient Enrollment for Phase III Trial of Lung Cancer Drug

BRIEF-Dizal Completes Enrollment For Its Phase II Pivotal Study of Sunvozertinib vs Platinum Doublet